Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954

被引:166
|
作者
Bridgewater, JA
Springer, CJ
Knox, RJ
Minton, NP
Michael, NP
Collins, MK
机构
[1] CHESTER BEATTY LABS,CRC,CTR CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND
[2] INST CANC RES,CRC,CTR CANC THERAPEUT,SUTTON SM2 5NG,SURREY,ENGLAND
[3] CTR APPL MICROBIOL & RES,DIV RES,DEPT MOLEC MICROBIOL,SALISBURY SP4 0JG,WILTS,ENGLAND
关键词
gene therapy; nitroreductase; CB1954; Herpes simplex thymidine kinase; ganciclovir; VDEPT; GDEPT; prodrugs;
D O I
10.1016/0959-8049(95)00436-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A recombinant retrovirus encoding E. coli nitroreductase (NTR) was used to infect mammalian cells. NIH3T3 cells expressing NTR were killed by the prodrug CB1954, which NTR converts to a bifunctional alkylating agent. Admitted, unmodified NIH3T3 cells could also be killed. In contrast to the Herpes simplex virus (HSV) thymidine kinase (TK)/ganciclovir(GCV) enzyme/prodrug system, NTR/CB1954 cell killing was effective in non-cycling cells. Co-operative killing was observed when cells expressing both NTR and TK were treated with a combination of CB1954 and GCV. NTR expression in human melanoma, ovarian carcinoma or mesothelioma cells also rendered them sensitive to GB1954 killing. These data suggest that delivery of the NTR gene to human tumours, followed by treatment with CB1954, may provide a novel tumour gene therapy approach.
引用
收藏
页码:2362 / 2370
页数:9
相关论文
共 27 条
  • [21] Virus-directed enzyme prodrug therapy (VDEPT): A clinical trial of adenovirus-delivered nitroreductase (NTR) in combination with CB1954 in patients with primary or secondary liver cancer
    Palmer, DH
    Mautner, V
    Hull, D
    Ellis, J
    Mountain, A
    Searle, P
    Young, LS
    Gerritsen, W
    James, ND
    Kerr, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 230S - 230S
  • [22] Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
    Djeha, AH
    Hulme, A
    Dexter, MT
    Mountain, A
    Young, LS
    Searle, PF
    Kerr, DJ
    Wrighton, CJ
    CANCER GENE THERAPY, 2000, 7 (05) : 721 - 731
  • [23] Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
    A Hakim Djeha
    Alison Hulme
    Michael T Dexter
    Andrew Mountain
    Lawrence S Young
    Peter F Searle
    David J Kerr
    Christopher J Wrighton
    Cancer Gene Therapy, 2000, 7 : 721 - 731
  • [24] Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954
    Jane A Plumb
    Alan Bilsland
    Rania Kakani
    Jiangqin Zhao
    Rosalind M Glasspool
    Richard J Knox
    T R Jeffry Evans
    W Nicol Keith
    Oncogene, 2001, 20 : 7797 - 7803
  • [25] Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954
    Plumb, JA
    Bilsland, A
    Kakani, R
    Zhao, JQ
    Glasspool, RM
    Knox, RJ
    Evans, TRJ
    Keith, WN
    ONCOGENE, 2001, 20 (53) : 7797 - 7803
  • [26] THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .1. PURIFICATION AND PROPERTIES OF A NITROREDUCTASE ENZYME FROM ESCHERICHIA-COLI - A POTENTIAL ENZYME FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)
    ANLEZARK, GM
    MELTON, RG
    SHERWOOD, RF
    COLES, B
    FRIEDLOS, F
    KNOX, RJ
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) : 2289 - 2295
  • [27] Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E-coli nitroreductase gene
    Green, NK
    Youngs, DJ
    Neoptolemos, JP
    Friedlos, F
    Knox, RJ
    Springer, CJ
    Anlezark, GM
    Michael, NP
    Melton, RG
    Ford, MJ
    Young, LS
    Kerr, DJ
    Searle, PF
    CANCER GENE THERAPY, 1997, 4 (04) : 229 - 238